Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 16, Issue 4 , Pages 513-527, August 2002

Clinical management potential tumours of low malignancy

Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA

Abstract 

Approximately 3000 American women are diagnosed with borderline ovarian tumours annually. Common signs and symptoms include abdominal/pelvic pain and a palpable adnexal mass. Pelvic sonography may be helpful, although not specific, in the diagnosis. Serum CA 125 is abnormal in only about 50% of patients. Primary surgery is the principal treatment; it consists of resection of the primary tumour(s) (frequently in the form of fertility-sparing surgery), frozen-section analysis and consideration of comprehensive surgical staging. The role of surgical staging remains unclear; further research is necessary. For patients with stage I disease, surgery alone is the standard. For patients with stage II–IV disease (with non-invasive or invasive peritoneal implants), the role of post-operative therapy remains unclear. Approximately 20–30% of the latter will relapse, frequently after several years. Most so-called recurrences are low-grade carcinomas. Potential predictive or prognostic factors include age, FIGO stage, residual disease and the micropapillary pattern. After fertility-sparing surgery, most patients retain normal reproductive function.

Keywords: borderline tumours, surgery, fertility

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  • f1 Address correspondence to: The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 440, Houston, Texas 77030, USA.

PII: S1521-6934(02)90308-1

doi:10.1053/beog.2002.0308

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 16, Issue 4 , Pages 513-527, August 2002